Enzo Biochem Inc (ENZ)

9.04
0.03 0.33
NYSE : Health Care
Prev Close 9.07
Open 9.14
Day Low/High 9.01 / 9.14
52 Wk Low/High 4.88 / 9.68
Volume 127.67K
Avg Volume 253.80K
Exchange NYSE
Shares Outstanding 46.29M
Market Cap 413.85M
EPS 1.00
P/E Ratio 12.96
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

We initiated one new position and exited another last week, while several other names reported earnings.

Adding a Life Sciences/Biotech Name

Wading in small on Enzo Biochem.

Commit To Purchase Enzo Biochem At $7.50, Earn 11.9% Annualized Using Options

Commit To Purchase Enzo Biochem At $7.50, Earn 11.9% Annualized Using Options

Investors considering a purchase of Enzo Biochem, Inc. stock, but tentative about paying the going market price of $8.69/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enzo Biochem's Clinical Laboratory Named An In-Network Provider To The Fourth Largest National Insurer

Enzo Biochem's Clinical Laboratory Named An In-Network Provider To The Fourth Largest National Insurer

Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Laboratory subsidiary, a full-service clinical laboratory with a specialty in women's health, today reached an agreement with the nation's fourth largest...

Enzo Biochem Reports Increased Second Quarter Operating Results

Enzo Biochem Reports Increased Second Quarter Operating Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported continued strong growth in operating results for the fiscal quarter and six months ended January 31, 2017.

Enzo Biochem Re-Schedules Teleconference To Discuss Second Quarter 2017 Results For This Afternoon, Monday, March 13, 2017 At 4:30 PM E.D.T. Due To Impending Storm

Enzo Biochem Re-Schedules Teleconference To Discuss Second Quarter 2017 Results For This Afternoon, Monday, March 13, 2017 At 4:30 PM E.D.T. Due To Impending Storm

Enzo Biochem, Inc. (NYSE:ENZ), has rescheduled its planned conference call to discuss fiscal 2017 second quarter results for this afternoon, Monday, March 13, 2017, at 4:30 PM E.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2017 Results Tuesday, March 14, 2017 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2017 Results Tuesday, March 14, 2017 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2017 second quarter results, Tuesday, March 14, 2017, at 8:30 AM E.

Enzo Biochem Reports Improved First Quarter Results

Enzo Biochem Reports Improved First Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported strong operating results for the first fiscal quarter ended October 31, 2016, with significant operating profit achieved at Enzo Clinical Labs.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2017 Results Friday, December 9, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2017 Results Friday, December 9, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2017 first quarter results, Friday, December 9, 2016, at 8:30 AM E.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EBR, EBR.B, ENZ, NTRA Downgrades: MBLY Initiations: SRAX Read on to get TheStreet Quant Ratings' detailed report:

Enzo Biochem Reports Strong 2016 Operating Results

Enzo Biochem Reports Strong 2016 Operating Results

Enzo Biochem Inc. (NYSE:ENZ) today reported strong results for the fourth quarter and fiscal year ended July 31, 2016, paced by revenue growth, margin expansion and litigation successes.

Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter 2016 And Full Year Results Friday, October 14, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter 2016 And Full Year Results Friday, October 14, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 fourth quarter and full year results, Friday, October 14, 2016, at 8:30 AM E.

Enzo Biochem Announces New York State Health Department Approval Of New Easily Adaptable, Cost Effective Cardiac Assay

Enzo Biochem Announces New York State Health Department Approval Of New Easily Adaptable, Cost Effective Cardiac Assay

Enzo Biochem, Inc. (NYSE: ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' PLAQPRO™ Lp-PLA 2 Assay.

Enzo Biochem is Now Oversold (ENZ)

Enzo Biochem is Now Oversold (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Enzo Biochem (ENZ)

Oversold Conditions For Enzo Biochem (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Decreases By 30.7% For ENZ

Short Interest Decreases By 30.7% For ENZ

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 661,112 share decrease in total short interest for Enzo Biochem, Inc. , to 1,494,651, a decrease of 30.67% since 06/15/2015.

Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement In Delaware With Illumina, Inc.

Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement In Delaware With Illumina, Inc.

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc.

Enzo Biochem Added To Russell 2000, Russell 3000 And Russell Global Indexes

Enzo Biochem Added To Russell 2000, Russell 3000 And Russell Global Indexes

Enzo Biochem (NYSE:ENZ) announced that it has been included in the broad-market Russell 3000® Index, Russell 2000® Index and Russell Global Index, which reconstituted after the market closed on Friday, June 24 th.

These Undervalued Stocks Are Unfairly Overlooked

These Undervalued Stocks Are Unfairly Overlooked

David Marcus, portfolio manager for the Evermore Global Value Fund, is trying to change that perception.

Enzo Biochem Reports Fiscal Third Quarter Results

Enzo Biochem Reports Fiscal Third Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the third fiscal quarter and nine months ended April 30, 2016, with strong across the board advances.

Enzo Biochem Announces New York State Approval Of New Women's Test Based On Proprietary Technology

Enzo Biochem Announces New York State Approval Of New Women's Test Based On Proprietary Technology

Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' AmpiProbe Candidiasis™ assay, the Company's second test aimed...

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 third quarter results, Wednesday, June 8, 2016, at 8:30 AM E.

Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement In Delaware With Life Technologies Corporation

Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement In Delaware With Life Technologies Corporation

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc.

Enzo Biochem Submits AmpiProbe Based Assay Targeted At Women's Health For Approval To New York State Department Of Health

Enzo Biochem Submits AmpiProbe Based Assay Targeted At Women's Health For Approval To New York State Department Of Health

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has submitted to the New York State Department of Health a validation package for its newest AmpiProbe™ based assay -- designed to identify the presence of the...

Enzo Biochem Reports Increased Fiscal Second Quarter Results

Enzo Biochem Reports Increased Fiscal Second Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the second fiscal quarter and fiscal first half ended January 31, 2016, led by strong gains at Enzo Clinical Labs reflecting increased molecular diagnostic testing...

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2016 Results Thursday, March 10, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2016 Results Thursday, March 10, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 second quarter results, Thursday, March 10, 2016, at 8:30 AM E.

Enzo Biochem Collects $7 Million From Court Approved Escrow Fund Closings

Enzo Biochem Collects $7 Million From Court Approved Escrow Fund Closings

Enzo Biochem, Inc. (NYSE:ENZ) and wholly-owned Enzo Life Sciences, Inc.

Enzo Biochem Updates Corporate Developments At Annual Shareholders Meeting

Enzo Biochem Updates Corporate Developments At Annual Shareholders Meeting

Enzo Biochem Inc. (NYSE:ENZ) announced the results of its Annual Shareholders Meeting today and updated shareholders on its businesses.